Compare JMSB & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JMSB | TTRX |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.2M | 298.8M |
| IPO Year | 2022 | 2025 |
| Metric | JMSB | TTRX |
|---|---|---|
| Price | $22.95 | $11.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $27.00 | $25.00 |
| AVG Volume (30 Days) | 71.2K | ★ 131.9K |
| Earning Date | 10-28-2026 | 11-25-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | ★ 24.17 | N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.08 | N/A |
| Revenue Next Year | $151.36 | $900.00 |
| P/E Ratio | $24.52 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.50 | $2.57 |
| 52 Week High | $24.26 | $16.45 |
| Indicator | JMSB | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.89 | 43.50 |
| Support Level | $22.75 | $9.02 |
| Resistance Level | $24.09 | $14.39 |
| Average True Range (ATR) | 0.39 | 1.44 |
| MACD | -0.02 | -0.42 |
| Stochastic Oscillator | 48.48 | 1.44 |
John Marshall Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits, and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.